Digital Health/Clinical Trials Newsletter
Information Mediary Corp. (IMC)
We build tools and technologies to provide medication adherence insights, cold chain and smart drug logistics
IMC announces a new programme astutely designed for projects with funding grants under $25,000. To alleviate your?clinical research?budget pressure, IMC is providing a comprehensive array of?medication adherence?tools, devices, support, and sophisticated software analytics - all for a nominal total cost of not more than $2,500 covering up to 2 full years of your requirements.?Read more.
Traditionally, recording clinical trial data is a paper-based process, which raises several challenges. What’s more, each laboratory normally has its own separate database to record results, which makes integrating data from multiple sites a complicated and multi-step process, prone to errors and delays.?Discover how a centralized lab database can improve decision-making in drug development by enabling real-time access to clinical trial data.
Of the differing types of simulation companies portrayed in this article—predicting drug performance in people, designing optimal protocols, or inviting patients to play-act roles in clinical trials—all say their businesses are growing and repeat customers are the norm. The case studies are impressive, highlighting money saved and FDA approvals achieved.
In a recent interview and software demonstration, Rohit Nambisan, CEO of Lokavant, and Craig Lipset, founder of Clinical Innovation Partners and Lokavant advisory board member, briefed?Applied Clinical Trials?on what current uses of real-world data and analytics can mean to clinical trial execution.
The Food and Drug Administration?published new guidance Aug. 31, 2023,?stating that some studies using real-world data (RWD) do not require investigational new drug (IND) applications and describing considerations for fulfilling postmarket study requirements.